BillionToOne

BillionToOne developed technology addressing a critical gap in non-invasive prenatal testing. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Pregnant women undergoing standard NIPTs could only detect chromosomal abnormalities like Down syndrome, missing recessive genetic conditions that carriers unknowingly passed to fetuses. This limitation hit hardest among populations with higher carrier frequencies for conditions like cystic fibrosis and sickle cell disease, creating disparate health outcomes. The problem was measurable: thousands of affected pregnancies went undetected annually despite available maternal blood samples. Existing alternatives—invasive amniocentesis or separate carrier screening tests—either carried miscarriage risk or required additional appointments and costs. Early validation came from genetic counselors and maternal-fetal medicine specialists who consistently reported patient demand for comprehensive screening. Pilot data showing their molecular counter could detect rare fetal DNA fragments with 1,000-fold greater sensitivity provided technical proof. Obstetric practices immediately adopted Unity Screen, validating that clinicians would integrate more comprehensive testing into standard workflows when accessible through a single blood draw.

BillionToOne operated in non-invasive prenatal testing (NIPT) and liquid biopsy diagnostics, a crowded space dominated by established players like Illumina, Natera, and Myriad Genetics. The company's core differentiation centered on its proprietary DNA molecular counter technology, which achieved 1,000-fold improvement in cell-free DNA resolution. While competitors offered standard aneuploidies screening, BillionToOne claimed the only NIPT capable of detecting recessive genetic conditions alongside chromosomal abnormalities from a single maternal blood draw. This distinction mattered significantly to customers—obstetricians and genetic counselors sought more comprehensive risk assessment without additional testing. Early validation came through clinical adoption and the successful commercialization of Unity Screen, suggesting hospitals and clinics valued the expanded diagnostic capability. The company's ability to address a genuine clinical gap—recessive condition detection had previously required separate testing—provided clear product-market fit that justified premium positioning against incumbents.